GLY 230

Drug Profile

GLY 230

Alternative Names: EXO-230; GLY-230

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator Exocell
  • Developer Glycadia
  • Class Small molecules
  • Mechanism of Action Glycosylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Diabetic nephropathies; Diabetic retinopathy

Most Recent Events

  • 07 Feb 2011 No development reported - Preclinical for Alzheimer's disease in USA (PO)
  • 07 Feb 2011 No development reported - Phase-I/II for Diabetic nephropathies in USA (PO)
  • 30 Apr 2009 Preclinical trials in Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top